secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-07-14T20:21:27+00:00
Accession:  0001437749-26-023538
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed presents new neflamapimod data at AAIC 2026; supports Phase 3 dose 50 mg TID in DLB
--------------------------------------------------------------------------------

- New analyses from Phase 2b RewinD-LB show neflamapimod slowed worsening in DLB patients with low pTau181 and adequate drug exposure.
- Neflamapimod produced durable slowing of basal forebrain atrophy over 48 weeks and increased basal forebrain connectivity vs placebo.
- Phase 2 study of 80 mg BID met primary safety, tolerability, and PK objectives; encouraging secondary clinical activity findings.
- PK-PD analysis identifies plasma trough threshold ~4 ng/mL; 50 mg TID dose expected to achieve threshold in ~90% of patients.
- Company gained alignment with FDA, EMA, MHRA, and PMDA for planned Phase 3 trial in DLB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/0001437749-26-023538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/crvo20260714_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-023538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer